Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has been given a consensus rating of “Moderate Buy” by the nine brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $22.25.

Several analysts have recently issued reports on the stock. Stifel Nicolaus set a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Thursday, February 26th. Raymond James Financial began coverage on shares of Phathom Pharmaceuticals in a research note on Thursday, December 11th. They set a “strong-buy” rating and a $28.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Phathom Pharmaceuticals in a report on Wednesday, January 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Guggenheim boosted their price target on shares of Phathom Pharmaceuticals from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, February 27th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in Phathom Pharmaceuticals during the 4th quarter worth about $27,000. Jones Financial Companies Lllp boosted its stake in shares of Phathom Pharmaceuticals by 442.6% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company’s stock valued at $30,000 after buying an additional 2,058 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Phathom Pharmaceuticals during the second quarter worth about $30,000. Kestra Advisory Services LLC acquired a new position in shares of Phathom Pharmaceuticals during the fourth quarter worth about $38,000. Finally, Ameritas Investment Partners Inc. increased its stake in shares of Phathom Pharmaceuticals by 39.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company’s stock worth $41,000 after buying an additional 1,216 shares during the period. 99.01% of the stock is owned by institutional investors and hedge funds.

Phathom Pharmaceuticals Trading Up 1.7%

PHAT stock opened at $11.15 on Friday. The business’s fifty day moving average price is $12.59 and its 200 day moving average price is $13.44. Phathom Pharmaceuticals has a 12-month low of $2.21 and a 12-month high of $18.31. The company has a market capitalization of $878.62 million, a PE ratio of -3.64 and a beta of 0.51.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its earnings results on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $57.58 million for the quarter, compared to analysts’ expectations of $57.44 million. Research analysts predict that Phathom Pharmaceuticals will post -4.78 EPS for the current fiscal year.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.